Meeting
2015 ASCO Annual Meeting
Tamoxifen (TAM)-induced severe hot flashes (HF): Is dose reduction (DR) a safe and effective strategy?
Authors
Clara Inkyung Lee
Westmead Hospital, Sydney, Australia
Clara Inkyung Lee , Peter Fox , Bavanthi Balakrishnar , Rosemary L Balleine , Bo Gao , Pamela Provan , Sally Coulter , Mark Tomlins , Christopher Liddle , Rina Hui , Mark Wong , Howard Gurney , Nicholas Wilcken
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—HER2/ER
Track
Breast Cancer
Sub Track
ER+
Citation
J Clin Oncol 33, 2015 (suppl; abstr 557)
DOI
10.1200/jco.2015.33.15_suppl.557
Abstract #
557
Poster Bd #
45
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Effect of PK-guided tamoxifen dose escalation on endoxifen serum concentrations in CYP2D6 intermediate and poor metabolizers.
First Author: Frans Opdam
Poster
2023 ASCO Quality Care Symposium
Chemo-Toxicity Calculator use in shared decision-making for chemotherapy treatment planning.
First Author: Alonso Victor Pacheco
Poster
2023 ASCO Breakthrough
The impact of low muscle mass and strength on chemotherapy toxicity in women with early breast cancer.
First Author: Andree Kurniawan Jr.
Poster
2023 ASCO Annual Meeting
Real-world experience of an in-house dihydropyrimidine dehydrogenase (DPYD) genotype test to guide fluoropyrimidine (FP) dosing at a multisite cancer hospital.
First Author: Jai Narendra Patel